Literature DB >> 22963963

[Unusual clinical presentation of cutaneous leishmaniasis in three diabetic patients].

S Chiheb1, L Oudrhiri, K Zouhair, M Soussi Abdallaoui, M Riyad, H Benchikhi.   

Abstract

INTRODUCTION: Cutaneous leishmaniasis (CL) is a parasitic infection characterized by significant clinical variability. Unusual and atypical clinical aspects of infection have been reported in immunodeficient patients or associated with particular parasite species. We report three cases of CL from foci of Leishmania major with a particular clinical presentation in diabetic patients. OBSERVATIONS: Patient 1: a 37-year-old man was admitted to the dermatology department for cutaneous vegetative ulcers spreading to the dorsal surface of the foot. History-taking revealed a stay in Er-Rachidia (East of Morocco, a known focus of CL L. major) six weeks earlier. Diabetes mellitus type I was discovered during hospitalization. The patient's 43-year-old sister (patient 2), diabetic for 6 years, consulted for a single leg ulcer appearing 3 months after the same trip to Er-Rachidia. Patient 3: a 61-year-old patient with a 7-year history of diabetes and under oral antidiabetics presented an extended vegetative lesion of the posterior surface of the leg 2 months after staying in Er-Rachidia. A diagnosis of CL was retained on the basis of epidemiology and history (living in an endemic areas of leishmaniasis), coupled in patients 1 and 3 with microbiological evidence involving identification of Leishmania bodies in skin smears or skin biopsies. All patients were treated with two intra-lesional injections per week of meglumine antimony (Glucantime(®)) for 6 weeks. The outcome was marked in all cases by healing of lesions and persistent pigmented scarring. DISCUSSION: We described three particular clinical aspect of CL emerging from a known focus of L. major, where infection is classically associated with vegetative or ulcero-vegetative lesions. This unusual profile suggests the role of factors related to parasite species and/or diabetes found in our three patients.
Copyright © 2012 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22963963     DOI: 10.1016/j.annder.2012.05.013

Source DB:  PubMed          Journal:  Ann Dermatol Venereol        ISSN: 0151-9638            Impact factor:   0.777


  6 in total

Review 1.  The Binomial Parasite-Host Immunity in the Healing Process and in Reactivation of Human Tegumentary Leishmaniasis.

Authors:  Fatima Conceição-Silva; Jessica Leite-Silva; Fernanda N Morgado
Journal:  Front Microbiol       Date:  2018-06-19       Impact factor: 5.640

Review 2.  The global diabetes epidemic: what does it mean for infectious diseases in tropical countries?

Authors:  Reinout van Crevel; Steven van de Vijver; David A J Moore
Journal:  Lancet Diabetes Endocrinol       Date:  2016-08-04       Impact factor: 32.069

3.  Unbalanced production of LTB4/PGE2 driven by diabetes increases susceptibility to cutaneous leishmaniasis.

Authors:  Icaro Bonyek-Silva; Sara Nunes; Reinan L Santos; Filipe R Lima; Alexsandro Lago; Juliana Silva; Lucas P Carvalho; Sergio M Arruda; Henrique C Serezani; Edgar M Carvalho; Claudia I Brodskyn; Natalia M Tavares
Journal:  Emerg Microbes Infect       Date:  2020-12       Impact factor: 7.163

4.  Diabetes Modifies the Clinic Presentation of Cutaneous Leishmaniasis.

Authors:  Alexsandro S Lago; Filipe R Lima; Augusto M Carvalho; Camilla Sampaio; Neuza Lago; Luiz H Guimarães; Jamile Lago; Paulo R L Machado; Lucas P Carvalho; Sérgio Arruda; Edgar M Carvalho
Journal:  Open Forum Infect Dis       Date:  2020-10-19       Impact factor: 3.835

5.  An Atypical Presentation of Cutaneous Leishmaniasis.

Authors:  Fatimazahra Chahboun; Madiha Eljazouly; Maha Alj; Soumiya Chiheb
Journal:  Cureus       Date:  2022-03-04

6.  Amputation of a type II diabetic patient with cutaneous leishmaniasis due to Leishmania major.

Authors:  Arezki Izri; Amina Bendjaballah-Laliam; Denis Sereno; Ihcene Kherachi Djenad; Zoubir Harrat; Mohammad Akhoundi
Journal:  BMC Infect Dis       Date:  2021-12-07       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.